Drug Diversion Monitoring 2022
What Outcomes Are Provider Organizations Achieving?

Author
Jackson Tate

Author
Jennifer Hickenlooper

June 21, 2022 | Read Time: 6 minutes

Drug diversion monitoring continues to be a top area of interest for pharmacy departments across the US as they seek to understand which products can effectively identify non-compliant behavior and otherwise unknown diverters. This report—KLAS’ first to analyze the performance of several vendors in this area—looks at which vendors are consistently delivering guidance, analytics, and insights that help organizations identify and prevent drug diversion. In addition, this report examines the outcomes provider organizations are achieving and how well vendors follow through on commitments.

to see the full dataset.

If you don't have a login, getting started is easy.

Provider Organizations

Fill out our registration form to verify your organization.

HIT Companies

Contact a KLAS representative for plans and pricing.

Key Findings:

Kit Check Customers Say High Ease of Use Facilitates Outcomes
Protenus’ Proactive Diversion Insights Guide Customer Investigations
Despite Mixed Experience with BD’s Guidance & Support, Customers Feel Optimistic about the Future
Customer Satisfaction with Imprivata (Limited Data) Has Significantly Declined

Writer
Sarah Hanson

Designer
Jessica Bonnett

Project Manager
Mary Bentley

Download Report Brief Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.